A lab model tests which drugs can reach brain tumor cells
Original title: 3D Bioprinted Blood-Brain-Tumor Barrier Spheroid-Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS-Producing Ruthenium as a Potential Therapeutic Candidate.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done with cells in a lab, not in people.
The short version
Scientists built a tiny lab copy of the brain's drug barrier to see which cancer drugs get through.
What was studied. Researchers printed small 3D balls of cells that act like the barrier around a brain tumor. They used a human glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary cell line, U-87MG, and tested four drugs on it.
What they found. Paclitaxel and cisplatin did not pass through the barrier in these models. temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary and a compound made with the metal ruthenium did pass through, and both killed many tumor cells. The ruthenium compound killed more tumor cells than temozolomide did in these models.
What this means, and what it doesn't
What it could mean: This gives researchers a new way to check if a drug can reach a brain tumor before testing it in people. It also points to ruthenium as a compound worth more study.
What it doesn't mean: This was done in cells in a lab, not in people. No patient was treated. The ruthenium compound is not a medicine you can get or ask for. It is not a cure, and it is many years and many studies away from everyday care.
Source: PubMed, October 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.